Navigation Links
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Date:3/12/2009

igational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate D-3263, the Company's lead small molecule candidate which targets TRPM8 (a transmembrane cation channel protein), in a Phase 1 dose escalation study in cancer. The application was cleared by the FDA in January 2009.

"This is an exciting time for Dendreon as we await the completion of the final analysis of our IMPACT trial, expected by the end of April. The 20 percent reduction in the risk of death that we saw in the PROVENGE arm at our interim analysis is encouraging to us," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "Our mission is to bring PROVENGE to the many prostate cancer patients seeking treatment alternatives that offer a meaningful survival benefit coupled with a more tolerable safety profile than current options, ultimately translating the success of PROVENGE into a platform of products that could benefit patients with many different types of cancer."

Dendreon expects to have final results from the IMPACT trial in April. The Company expects to host a conference call after the data from the IMPACT trial are known.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage ... including high value and difficult to manufacture proteins, today ... 6,000,000 shares of its common stock at a price ... shares being offered, 2,610,000 are being offered by Pfenex ... existing stockholders. Pfenex will not receive any proceeds from ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... 2015 /CNW/ - A new and innovative service has ... North America,s largest packaging trade ... in the "Sustainability, service" category of the PAC ... Comparison" is a service that scores clients, packaging ... peers. This benchmarking process shows clients how their ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology and medical device industries, with operations ... the United States , today announced that it ... 2015 after the New York Stock Exchange closes on ... May 14, 2015 Shanghai time). The earnings release will ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, ... National Institutes of Health (NIH) Director,s Opportunity Award for ... Better Treatments" under the American Recovery & Reinvestment Act ...
... Medicago Inc. (TSX: MDG), a biotechnology company focused ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... applications under the Patent Cooperation Treaty (PCT) that ... proteins and VLPs. "The extraction and ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 3Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 2Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 3
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Purdue University biochemist has demonstrated a process using nanotechnology ... which may help reduce drug side effects. W. ... developed a nanopolymer that can be coated with drugs, ... in the cells the drug has entered. Since they,re ...
... WEST LAFAYETTE, Ind. - Chemical changes in tree leaves ... climate change may reduce the availability of soil nutrients, ... an associate professor of forestry and natural resources, found ... tannin when exposed to hot, droughtlike conditions. Those tannins, ...
... an eco-friendly diesel fuel have more red lights in their ... completely green would not only bend the laws of physics, ... limited, and since we can,t use more than what Earth ... sources like algae," said Peter Pfromm, professor of chemical engineering ...
Cached Biology News:Nanopolymer shows promise for helping reduce cancer side effects 2Drought-exposed leaves adversely affect soil nutrients, study shows 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 4
POU domain, class 2, transcription factor 2,...
... HEK 293T cell line contains the b-lactamase ... response element (CRE). To obtain the cell ... HEK 293T cells by lentivirus. Subsequent flow ... to forskolin stimulation (Figure 1). The CellSensor ...
activating transcription factor 4 (tax-responsive enhancer element B67),...
Reactivity: Human...
Biology Products: